IgA nephropathy (IgAN) is characterized by the deposition of IgA1-containing immune complexes in the glomerular mesangium. The pathogenesis follows a 4-hit cascade: ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce the ...

Immunoglobulin A (IgA) nephropathy is a condition that causes a certain type of protein to build up in your kidneys. It progresses differently in everyone. Your kidneys might still work well years ...

IgA Nephropathy Foundation: “IgA Nephropathy – What You Need to Know.” Cleveland Clinic: “IgA Nephropathy.” National Institute of Diabetes and Digestive and Kidney Diseases ...

Phase 3 VISIONARY study met its primary endpoint at the prespecified interim analysis; sibeprenlimab demonstrated a statistically significant and clinically meaningful reduction in 24-hour uPCR ...

The BLA submission, Otsuka's first, is supported by results from the Phase 2 ENVISION clinical trial (NCT04287985) and the Phase 3 VISIONARY clinical trial (NCT05248646), which met its primary ...

Fibroblast activating protein inhibitor (FAPI) PET/CT imaging may be a non-invasive modality to monitor IgA nephropathy (IgAN) progression, preliminary study results suggest.

Andrew S. Bomback, MD, MPH, recalls a patient from over a decade ago, who traveled to New York for a second opinion on his IgA nephropathy diagnosis. The patient had researched his condition and ...

IgA Nephropathy Foundation Leadership and IgAN Patients pose for a photo at SPARK IgA Nephropathy Foundation celebrates 20 years of advocac ...